Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-09-15
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3152
Patent
active
058078614
ABSTRACT:
A method for treating a disease caused by an undesirable cell response mediated by a proliferative intracellular signaling pathway is provided wherein an effective amount of a compound is administered. The compound, resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof, has the formula
REFERENCES:
patent: 3245994 (1966-04-01), Klinger et al.
patent: 3422107 (1969-01-01), Mohler et al.
patent: 3737433 (1973-06-01), Mohler et al.
patent: 4061753 (1977-12-01), Bodor et al.
patent: 4144340 (1979-03-01), Offermans et al.
patent: 4275064 (1981-06-01), Bodor et al.
patent: 4279992 (1981-07-01), Boguslaski et al.
patent: 4299832 (1981-11-01), Brown et al.
patent: 4374837 (1983-02-01), Favier et al.
patent: 4515795 (1985-05-01), Hinze et al.
patent: 4542137 (1985-09-01), Klessing et al.
patent: 4558051 (1985-12-01), Sunshine et al.
patent: 4565817 (1986-01-01), Korbonits et al.
patent: 4576947 (1986-03-01), Hinze et al.
patent: 4618612 (1986-10-01), Baglioni
patent: 4636507 (1987-01-01), Kreutzer et al.
patent: 4784994 (1988-11-01), Romer et al.
patent: 4833146 (1989-05-01), Gebert et al.
patent: 4845081 (1989-07-01), Sloan
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5039666 (1991-08-01), Novick, Jr.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5118500 (1992-06-01), Hanel et al.
patent: 5126340 (1992-06-01), Tseng et al.
patent: 5196439 (1993-03-01), Sugimoto et al.
patent: 5247086 (1993-09-01), Cain et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: B13737433 (1987-03-01), Mohler et al.
Bianco et al., Blood, 76: Supplement 1 (522), p. 133a, "Pentoxifylline (PTX) and GM-CSF Decrease Tumor Necrosis Factor-ALPHA (TNF-.alpha.) Levels in Patients Undergoing Allogeneic Bone Marrow Transplantation (BMT)", 1990.
Bianco et al., Blood, 78:5, pp. 1205-1211, "Phase I-II Trial of Pentoxifylline for the Prevention of Transplant-Related Toxicities Following Bone Marrow Transplantation", Sep. 1991.
Bursten et al., The Journal of Biological Chemistry, vol. 266, No. 31, pp. 20732-20743, "Interleukin-1 Rapidly Stimulates Lysophosphatidate Acyltransferase and Phosphatidate Phpsphohydrolase activities in Human Mesangial Cells", Nov. 1991.
Davis et al., Applied Environment Microbial., 48:2, pp. 327-331, "Microbial Models of Mammalian Metabolism: Microbial Reduction and Oxidation of Pentoxifylline", Aug. 1984.
Ridder., Chemical Abstracts, vol. 60, col. 15892, "Derivatives of dialkylxanthines", Jan. 1964.
Singer et al., Bone Marrow Transplantation, 10:19, pp. 19-25, "Effect of Methylxanthine Derivatives on T Cell Activation", 1992.
Klein J. Peter
Kumar Anil M.
Leung David W.
Rice Glenn C.
Ridgers Lance H.
Cell Therapeutics Inc.
Spivack Phyllis G.
LandOfFree
Amine substituted xanthinyl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amine substituted xanthinyl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amine substituted xanthinyl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-87607